Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States
This article is protected by copyright. All rights reserved. (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - April 24, 2023 Category: Orthopaedics Authors: Min Kim,
Tzu ‐Chieh Lin,
Tarun Arora,
Hong Zhao,
Akhila Balasubramanian,
Robert Kees Stad,
James O'Kelly,
Leslie Spangler,
Brian D. Bradbury,
Jeffrey R. Curtis Tags: Research Article Source Type: research
1533 Repurposing bisphosphonates for reducing skin inflammation and promoting skin repair
Nitrogen-containing bisphosphonates (BPs) like zoledronic acid (ZA) have long been known for their remarkable inhibition of bone resorption and clinical use for osteopenia. In addition to effects on osteoclasts, BPs deposit in the skin and immune-rich tissue including the spleen and bone marrow and are known to limit macrophage activity. Therefore, we hypothesized BPs could be repurposed for skin conditions in which exaggerated host innate immune responses contribute to tissue pathology. Using our established wound model triggered by exposure to topical nitrogen mustard, an alkylating agent chemotherapeutic commonly used i...
Source: Journal of Investigative Dermatology - April 17, 2023 Category: Dermatology Authors: U. Onay, D. Biyashev, S.T. Evans, M. Demczuk, K.Q. Lu Source Type: research
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Curr Treat Options Oncol. 2023 Apr 15. doi: 10.1007/s11864-023-01082-3. Online ahead of print.ABSTRACTFor high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 - EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrated that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the Oly...
Source: Cancer Control - April 15, 2023 Category: Cancer & Oncology Authors: Jamie O Brett Erica L Mayer Source Type: research
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
Opinion statementFor high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 − EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrate d that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the OlympiA trial for high-risk disease in patients with germlineBRCA1/BRCA2 mu...
Source: Current Treatment Options in Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
Cisplatin and Zoledronic acid: two drugs combined in a Pt(II) complex with potential antitumor activity towards bone tumors and metastases.
Dalton Trans., 2023, Accepted Manuscript DOI: 10.1039/D3DT00734K, PaperAlessandra Barbanente, Nicoletta Ditaranto, Antonio Laghezza, Paolo Tortorella, Francesco Paolo Intini, Concetta Pacifico, Giovanni Natile, Nicola Margiotta Treatment of primary bone malignancies comprises surgery, radiotherapy, chemotherapy, and analgesics. Platinum-based chemotherapeutics, such as cisplatin, are commonly used for the treatment of bone cancer but, despite their success, outcomes... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Dalton Trans. latest articles)
Source: RSC - Dalton Trans. latest articles - April 13, 2023 Category: Chemistry Authors: Alessandra Barbanente Source Type: research
Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma
In this study, we discovered that z oledronic acid (ZOL) dramatically increased cell death in osteosarcoma cells, and this cytotoxicity was greatly reversed by liproxstatin-1 (a ferroptosis inhibitor). ZOL also had an obvious effect on lipid peroxidation and reactive oxygen species (ROS), which suggested that ZOL most certain ly induces ferroptosis in osteosarcoma cells. In addition, we further found that ZOL increases cytochrome P450 oxidoreductase (POR) expression dose dependently in osteosarcoma cell lines. Knockdown of POR attenuated ZOL-induced cytotoxicity and attenuated the effect of ferroptosis in osteo...
Source: Medical Oncology - April 10, 2023 Category: Cancer & Oncology Source Type: research
Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients
AbstractWe aimed to compare the efficacy of switching from romosozumab (RMAb) to denosumab (DMAb) or zoledronic acid (Zol) with respect to changes in bone mineral density (BMD) and bone metabolism. We also aimed to determine predictors of changes in BMD among patients who received sequential therapy from RMAb. One hundred patients who received RMAb therapy were recruited for this study. A total 49 patients received bisphosphonate (BP) pre-treatment and 51 received active vitamin D3 analog pre-treatment or no treatment. Forty-two patients were switched to Zol (BP –RMAb–Zol; 20 and RMAb–Zol; 22), and 58 patients were s...
Source: Calcified Tissue International - April 10, 2023 Category: Orthopaedics Source Type: research
Cancers, Vol. 15, Pages 2211: The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
li
Ingunn Holen
CDK 4/6 inhibitors have demonstrated significant improved survival for patients with estrogen receptor (ER) positive breast cancer (BC). However, the ability of these promising agents to inhibit bone metastasis from either ER+ve or triple negative BC (TNBC) remains to be established. We therefore investigated the effects of the CDK 4/6 inhibitor, palbociclib, using in vivo models of breast cancer bone metastasis. In an ER+ve T47D model of spontaneous breast cancer metastasis from the mammary fat pad to bone, primary tumour growth and the number of hind limb skeletal tumours were significantly lower in...
Source: Cancers - April 8, 2023 Category: Cancer & Oncology Authors: Lubaid Saleh Penelope D. Ottewell Janet E. Brown Steve L. Wood Nichola J. Brown Caroline Wilson Catherine Park Simak Ali Ingunn Holen Tags: Article Source Type: research
Zoledronic acid affects the process of Porphyromonas gingivalis infecting oral mucosal epithelial barrier: An in-vivo and in-vitro study
This study aimed to investigate the influences of ZA on the process of Porphyromonas gingivalis (P. gingivalis) infecting the gingival epithelial barrier via in-vitro and in-vivo experiments. In the in-vitro experiments, under the condition of different concentrations of ZA (0, 1, 10, and 100 μM), P. gingivalis was used to infect human gingival epithelial cells (HGECs). The infections were detected by transmission electron microscope and confocal laser scanning microscope. Besides, the internalization assay was applied to quantify the P. gingivalis, which infected the HGECs, in the different groups. To evaluate the expres...
Source: Frontiers in cellular and infection microbiology - March 28, 2023 Category: Microbiology Source Type: research
A Bone ‐Penetrating Precise Controllable Drug Release System Enables Localized Treatment of Osteoporotic Fracture Prevention via Modulating Osteoblast‐Osteoclast Communication
In this study, a featured radial extracorporeal shock wave (rESW) responsive nano-drug delivery system (NDDS) is developed for local treatment. Based on a mechanic simulation, a sequence of hollow zoledronic acid (ZOL)-contained nanoparticles (HZNs) with controllable shell thickness that predicts various mechanical responsive properties is constructed by controlling the deposition time of ZOL and Ca2+ on liposome templates. Attributed to the controllable shell thickness, the fragmentation of HZNs and the release of ZOL and Ca2+ can be precisely controlled with the intervention of rESW. Furthermore, the distinct effect of H...
Source: Small - March 27, 2023 Category: Nanotechnology Authors: Haojun Liang,
Kui Chen,
Jing Xie,
Lei Yao,
Yunpeng Liu,
Fan Hu,
Hao Li,
Yinze Lei,
Yujiao Wang,
Linwen Lv,
Ziteng Chen,
Sen Liu,
Qiuyang Liu,
Zhijie Wang,
Jiacheng Li,
Ya ‐Nan Chang,
Juan Li,
Hui Yuan,
Gengyan Xing,
Gengmei Xing Tags: Research Article Source Type: research
The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats
CONCLUSIONS: BPs can interfere with normal bone healing time by up-regulating the expression of Sema4D in tissues, leading to coupling disorder between osteoclasts and osteoblasts with inhibition of the maturation of osteoclasts, thereby inhibiting the growth of osteoblasts. Differentiation and expression of related osteogenic factors mediate the development of BRONJ.PMID:36970799 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - March 27, 2023 Category: Dentistry Authors: Qiao-Ting Pan Xiao-Long Zang Zhao-Wei Sun Meng-Qi Pan Xin-Mei Zhu Zhi-Yong Li Source Type: research
